Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis.

Poormoghim H, Moradi Lakeh M, Mohammadipour M, Sodagari F, Toofaninjed N.

Rheumatol Int. 2012 Aug;32(8):2431-44. doi: 10.1007/s00296-011-1967-y. Epub 2011 Jun 21. Review.

PMID:
21691743
2.

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.

Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.

Clin Rheumatol. 2007 Feb;26(2):168-72. Epub 2006 Apr 14.

PMID:
16614793
3.

Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.

Nannini C, West CP, Erwin PJ, Matteson EL.

Arthritis Res Ther. 2008;10(5):R124. doi: 10.1186/ar2534. Epub 2008 Oct 20. Review. Erratum in: Arthritis Res Ther. 2009;11(2):408.

4.

High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.

Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.

Int J Rheum Dis. 2009 Sep;12(3):239-42. doi: 10.1111/j.1756-185X.2009.01417.x.

PMID:
20374353
5.

Cyclophosphamide versus placebo in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group.

N Engl J Med. 2006 Jun 22;354(25):2655-66.

6.

Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.

Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laqué R, Vilardell-Tarrés M.

Clin Rheumatol. 2011 Nov;30(11):1393-8. doi: 10.1007/s10067-011-1823-1. Epub 2011 Sep 1.

PMID:
21881859
7.

Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.

Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP.

Lung. 2013 Oct;191(5):483-9. doi: 10.1007/s00408-013-9499-8. Epub 2013 Aug 8.

PMID:
23925736
8.

Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.

Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG.

Clin Exp Rheumatol. 2007 Sep-Oct;25(5):734-9.

PMID:
18078622
9.

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

Ann N Y Acad Sci. 2007 Sep;1110:271-84.

PMID:
17911442
10.

Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.

Ostojic P, Damjanov N.

Clin Rheumatol. 2006 Nov;25(6):819-21. Epub 2006 Jan 27.

PMID:
16440134
12.

Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide.

Abhishek A, Yazdani R, Pearce F, Regan M, Lim K, Hubbard R, Lanyon P.

Clin Rheumatol. 2011 Aug;30(8):1099-104. doi: 10.1007/s10067-011-1734-1. Epub 2011 Apr 12.

PMID:
21484227
13.

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.

White B, Moore WC, Wigley FM, Xiao HQ, Wise RA.

Ann Intern Med. 2000 Jun 20;132(12):947-54.

PMID:
10858177
15.

Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.

Fathi N, Furst DE, Clements PJ.

Curr Rheumatol Rep. 2007 May;9(2):144-50.

PMID:
17502045
16.
17.

Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.

Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S, Andalib E.

Rheumatol Int. 2014 Dec;34(12):1691-9. doi: 10.1007/s00296-014-3026-y. Epub 2014 May 7.

PMID:
24801572
18.

Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.

Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP, Toledano K, Dagan A, Bishara R, Markovits D, Nahir MA, Braun-Moscovici Y.

Isr Med Assoc J. 2015 Mar;17(3):150-6.

19.

Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.

Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.

Int J Rheum Dis. 2014 Nov;17(8):923-8. doi: 10.1111/1756-185X.12399. Epub 2014 May 26.

PMID:
24864029
20.

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

Gerbino AJ, Goss CH, Molitor JA.

Chest. 2008 Feb;133(2):455-60. Epub 2007 Dec 10.

PMID:
18071023
Items per page

Supplemental Content

Write to the Help Desk